A look behind the scenes into the planning of the AACR Annual Meeting, including the scientific program, conference logistics,...
Seven immune checkpoint inhibitors, targeting the PD-1, PD-L1, or CTLA-4 proteins, are currently approved for the treatment of cancer....
The most recent edition of The Cancer Letter features an op-ed from AACR President David A. Tuveson, MD, PhD,...
The new year brings a new chapter in the holy book of cancer biology with the publication in the...
Each year in the United States, about 14,480 women are diagnosed with cervical cancer, and about 4,290 women die of...
Guest Post by William G. Nelson, MD, PhDEditor-in-Chief, Cancer Today The size of the known universe is mind-boggling. At times,...
The recently launched Cancer Research Communications (CRC) is the latest addition to the AACR’s journal portfolio. The new journal...
Surrounding a tumor is a vast network of blood vessels, immune cells, proteins, and even bacteria, all of which...
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented...
We’re closing out 2021 on the blog with Editors’ Picks, our monthly staple featuring articles handpicked by the editors of the AACR...
On December 23, 1971, when President Richard Nixon signed the National Cancer Act of 1971 into law, cancer was considered a death sentence. Only 42 percent of those diagnosed with cancer survived five years past diagnosis,...